Results 31 to 40 of about 104,817 (211)

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan, García Foncillas, Jesús, Ronga, Philippe, Stintzing, Sebastian, Sunakawa, Yu, Wainberg, Zev, Witzler, Pauline   +6 more
core   +1 more source

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions

Allergology International
Background: Oxaliplatin is commonly used to treat gastrointestinal malignancies. However, its applications are limited due to potential adverse drug reactions (ADRs), particularly severe anaphylactic shock.
Hung-Chih Hsu, Wen-Hung Chung, Yung-Chang Lin, Tsai-Sheng Yang, John Wen-Cheng Chang, Chia-Hsun Hsieh, Shuen-Iu Hung, Chun-Wei Lu, Jen-Shi Chen, Wen-Chi Chou, Chuang-Wei Wang   +10 more
doaj   +1 more source

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. [PDF]

, 2017
BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein and amplification of the TOP2A gene have been associated with treatment response in colorectal and ...
Arguello, David, Gatalica, Zoran, Heestand, Gregory M, Kurzrock, Razelle, Schwaederle, Maria   +4 more
core   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer

Pharmaceuticals
Background/Objectives: The reversal effect of cGAMP, as a STING pathway regulator, on oxaliplatin resistance in colorectal cancer was investigated, and its mechanism was proposed.
Xiaoqing Wang, Meili Xi, Xing Lu, Xiangshi Tan   +3 more
doaj   +1 more source

Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1.

PLoS ONE, 2014
BackgroundEvidence suggests that many types of cancers are composed of different cell types, including cancer stem cells (CSCs). We have previously shown that the chemotherapeutic agent oxaliplatin induced epithelial-mesenchymal transition, which is ...
Yang Bu, Qing-An Jia, Zheng-Gang Ren, Ju-Bo Zhang, Xue-Mei Jiang, Lei Liang, Tong-Chun Xue, Quan-Bao Zhang, Yan-Hong Wang, Lan Zhang, Xiao-Ying Xie, Zhao-You Tang   +11 more
doaj   +1 more source

Unusual DNA binding modes for metal anticancer complexes [PDF]

, 2009
DNA is believed to be the primary target for many metal-based drugs. For example, platinum-based anticancer drugs can form specific lesions on DNA that induce apoptosis.
Pizarro, Ana M., Sadler, P. J.
core   +1 more source

Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature

Journal of Hematology & Oncology, 2010
Background Oxaliplatin is a platinum compound used in the treatment of gastrointestinal malignancies, including colorectal cancer. The incidence of hypersensitivity reaction in patients receiving oxaliplatin is approximately 15%, with severe reaction ...
Aster Richard H, Curtis Brian R, Chen Chien-Shing, Stevens W, Bautista Marnelli A, Hsueh Chung-Tsen   +5 more
doaj   +1 more source

Amifostine protects from the peripheral sensory neuropathy induced by oxaliplatin in mice [PDF]

Brazilian Journal of Medical and Biological Research, 2020
Sensory neuropathy is a dose-limiting side effect of oxaliplatin-based cancer treatment. This study investigated the antinociceptive effect of amifostine and its potential neuroprotective mechanisms on the oxaliplatin-related peripheral sensory ...
A.F. Pereira, J.A. Lino, B.W.F. Alves, M.R.P. Lisboa, R.B. Pontes, C.A.V.G. Leite, R.B. Nogueira, R.C.P. Lima-Júnior, M.L. Vale   +8 more
doaj   +2 more sources